Sanofi - American Depositary Shares (NQ:SNY)

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

A healthcare titan wants to buy the biotech's vaccines.

Topics Artificial Intelligence Economy Intellectual Property

Why Dynavax Stock Soared Today ↗

December 24, 2025

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...

Topics Artificial Intelligence Economy Intellectual Property

Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition

December 24, 2025

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...

Topics Economy

Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring

December 24, 2025

French drugmaker Sanofi agreed to acquire vaccine maker Dynavax in a $2.2 billion deal.

Topics Intellectual Property

Why Did Dynavax Stock Surge 38% In Premarket Today? ↗

December 24, 2025

Via Stocktwits

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Via Stocktwits

Topics Government

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

December 23, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics ETFs Economy Intellectual Property

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗

December 01, 2025

The comeback may have begun.

Topics Death

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

Sanofi stock dropped Wednesday after French authorities raided the firm's headquarters as part of a tax fraud investigation.

Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation ↗

November 26, 2025

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Topics Fraud

November 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines

November 14, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

Topics Artificial Intelligence Economy Product Recall

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Roche is great at developing drugs -- but is its stock a great buy?

Topics Artificial Intelligence Economy Intellectual Property

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

Topics Artificial Intelligence Intellectual Property

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Topics Artificial Intelligence

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗

Topics Animal Testing Artificial Intelligence Economy

October 28, 2025

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

Via Benzinga

UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

October 27, 2025

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

From Medidata Solutions, Inc.

Via GlobeNewswire

Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations

October 24, 2025

Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,...

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth expected.

Topics Government World Trade

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark ↗

October 24, 2025

Via Benzinga

Topics Earnings

Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion ↗

October 24, 2025

Sanofi stock jumped early Friday on better-than-expected quarterly sales.